Modeling the impact of enhanced depression treatment on workplace functioning and costs: A cost-benefit approach

Medical Care

Volumn 44, Issue 4, 2006, Pages 352-358

  Lo Sasso, Anthony T ^a   Rost, Kathryn ^b   Beck, Arne ^c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Economic analysis; Employer sponsored health insurance; Return on investment

Indexed keywords

ABSENTEEISM; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DEPRESSION; ECONOMICS; EMPLOYMENT; FEMALE; HEALTH CARE COST; HUMAN; MALE; MENTAL HEALTH SERVICE; OCCUPATIONAL HEALTH SERVICE; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICS; UNITED STATES; UTILIZATION REVIEW; WORKPLACE;

ABSENTEEISM; ADULT; COST-BENEFIT ANALYSIS; DEPRESSION; EFFICIENCY; EMPLOYER HEALTH COSTS; EMPLOYMENT; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MENTAL HEALTH SERVICES; MODELS, ECONOMETRIC; OCCUPATIONAL HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; WORKPLACE;

EID: 33645988567     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000204049.30620.1e     Document Type: Article

References (36)

1. Druss BG, Marcus SC, Olfson M, et al. Comparing the national economic burden of five chronic conditions. Health Affairs. 2001;2:233-241.
2. Kessler RC, Frank RG. The impact of psychiatric disorders on work loss days. Psychol Med. 1997;27:861-873.
3. Greenberg PE, Kessler RC, Nells TL Depression in the workplace: an economic perspective. In: Feighner JP BWF, ed. Selective Serotonin Re-Uptake Inhibitors: Advances in Basic Research and Clinical Practice. Chichester, West Sussex England: John Wiley & Sons, Ltd.; 1996.
4. Kessler RC, Michelson KD, Barber C The effects of chronic medical conditions on work impairment. In: Rossi AS, ed. Caring and Doing for Others; Social Responsibilities in the Domains of the Family, Work and Community. Chicago: University of Chicago Press; 1999.
5. Russell JM, Patterson J, Baker AM. Depression in the workplace: epidemiology, economics and effects of treatment. Disease Manage Health Outcomes. 1998;4:135-142.
6. Conti DJ, Burton WN. Behavioral health disability management. In: Oher JM, ed. The Employee Assistance Handbook. New York: John Wiley & Sons, Inc.; 1996.
7. Martin JK, Blum TC, Beach SRH, et al. Subclinical depression and performance at work. Social Psychiatry Psychiatric Epidemiol. 1996; 41:863-877.
8. Burton WN, Conti DJ, Chen C, et al. The real measure of productivity. Business Health. 1999;17:34-36.
9. Burton WN, Conti DJ, Chen C, et al. The role of health risk factors and disease on worker productivity. J Occup Environ Med. 1999;41:863-877.
10. Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA. 1999;289:3135-3144.
11. Rost K, Nutting P, Smith J, et al. Improving depression outcomes in community primary care practice: A randomized trial of the QuEST intervention. J Gen Intern Med. 2001;16:143-149.
12. Coulehan JL, Schulberg HC, Block MR, et al. Treating depressed primary care patients improves their physical, mental, and social functioning. Arch Intern Med. 1997;16:143-149.
13. Katzelnick DJ, Simon GE, Pearson SD, et al. Randomized trial of a depression management program in high utilizers of medical care. Arch Family Med. 2000;9:345-351.
14. Wells KB, Sherbourne CD, Schoenbaum M, et al. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA. 2000;283:212-220.
15. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press; 1997.
16. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
17. Pauly MV, Nicholson S, Xu J, et al. A general model of the impact of absenteeism on employers and employees. Health Econ. 2002;13:340-346.
18. Lerner D, Amick BC III, Lee JC, et al. Relationship of employee-reported work limitations to work productivity. Med Care. 2003;41: 649-659.
19. Lerner D, Amick BC III, Rogers WH, et al. The Work Limitations Questionnaire. Med Care. 2000;39:72-85.
20. Giampaoli S, Palmieri L, Copocaccia R, et al. Estimating population-based incidence and prevalence of major coronary events. Int J Epidemiol. 2001;30(Suppl):S5-S10.
21. Weinstein MC, Coxson PG, Williams LW, et al. Forecasting coronary heart disease incidence, mortality, and cost: The Coronary Heart Disease Policy Model. Am J Public Health. 1987;77:1417-1426.
22. Mowat FS, Bundy KJ. A mathematical algorithm to identify toxicity and prioitize pollutants in field sediments. Chemosphere. 2002;49:499-513.
23. Rost KM, Pyne JM, Dickinson LM, et al. Cost effectiveness of enhancing primary care depression management on an ongoing basis. Ann Family Med. 2005;3:7-14.
24. Rost K, Smith JL, Dickinson M. The effect of improving primary care depression management on employee absenteeism and productivity: a randomized trial. Med Care. 2004;42:1202-1210.
25. Nicholson S, Pauly MV, Polsky D, et al. Measuring the effects of workloss on productivity with team production. Health Econ. 2006;15: 111-123.
26. Sturm R. How can care for depression become more cost-effective? JAMA. 1995;273:51-58.
27. Employee Turnover - A critical human resource benchmark. 12-3-2002. HR Benchmarks. Employment Policy Foundation.
28. Kessler RC, Barber C, Beck A, et al. The World Health Organization: Health and Work Performance Questionnaire. J Occup Environ Med. 2003;45:1-19.
29. Severens J, Prines JB, van der Wilt GJ, et al. Cost-effectiveness of cognitive behavior therapy for patients with chronic fatigue syndrome. Q J Med. 2004;97:153-161.
30. Puolakka K, Kautiainen H, Mottonen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized follow-up trial. Arthritis Rheumatoid. 2005;50:55-62.
31. Gerth WC, Sarma S, Hu XH, et al. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med. 2004;46:48-54.
32. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatric Res. 2003;12:22-33.
33. Leon AC, Walkup JT, Portera L. Assessment and treatment of depression in disability claimants: A cost-benefit simulation study. J Nervous Mental Dis. 2002;190:3-9.
34. Goetzel RZ, Ozminkowski RJ, Villagra VG, et al. A review of the literature: return on investment for selected disease management programs. Health Care Financing Rev., in press.
35. Fireman B, Bartlett J, Selby J. Can disease management reduce health care costs by improving quality? Health Affairs. 2004;23:63-75.
36. Goetzel RZ, Ozminkowski RJ, Villagra VG, et al. Return on investment in disease management: a review. Health Care Financing Rev. 2005;26: 1-19.